Specific Use-result Surveillance of Spiriva Respimat in Asthmatics

Specific Use-result Surveillance of Spiriva Respimat in Asthmatics (Patients With Severe Persistent Asthma)

The safety of Spiriva® 2.5 µg Respimat® 60 puffs (hereinafter referred to as Spiriva® Respimat®) in patients with severe persistent asthma under the real-world use was not confirmed in clinical trials.

Inclusion criteria:

• Patients diagnosed with severe persistent bronchial asthma
• Patient aged >= 15 years
• Patients who are naive to Spiriva Respimat and receive Spiriva Respimat for the first time for treatment of bronchial asthma on top of at least ICS (Inhaled corticosteroids) treatment.

Exclusion criteria:

• Patients who have a contraindication to Spiriva Respimat defined in the package insert for Spiriva Respimat
• Patients who have been enrolled this study before.